Literature DB >> 30044044

Continuous infusion of extended half-life factor VIII (efmoroctocog alpha) for surgery in severe haemophilia A.

I C L Kremer Hovinga1, R E G Schutgens1, P R van der Valk1, L F D van Vulpen1, E P Mauser-Bunschoten1, K Fischer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30044044     DOI： 10.1111/hae.13557

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  4 in total

1.  Case report: successful perioperative management of patients with haemophilia A using an extended half-life factor VIII (Efmoroctocog alfa) during neurosurgical procedures.

Authors:  Florian Kocher; Andreas Seeber; Johannes Kerschbaumer; Stefan Schmidt; Dominik Wolf; Clemens Feistritzer
Journal:  Ther Adv Hematol       Date:  2021-03-31

Review 2.  Recombinant factor VIII Fc for the treatment of haemophilia A.

Authors:  Cedric Hermans; Maria Elisa Mancuso; Beatrice Nolan; K John Pasi
Journal:  Eur J Haematol       Date:  2021-03-31       Impact factor: 2.997

3.  Continuous Infusion of Factor VIII and von Willebrand Factor in Surgery: Trials with pdFVIII LFB or pdVWF LFB in Patients with Bleeding Disorders.

Authors:  Jerzy Windyga; Benoît Guillet; Lucia Rugeri; Alexandra Fournel; Ewa Stefanska-Windyga; Valérie Chamouard; Sonia Pujol; Céline Henriet; Françoise Bridey; Claude Négrier
Journal:  Thromb Haemost       Date:  2022-05-31       Impact factor: 6.681

4.  Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins: Real-world experience in the Nordic countries.

Authors:  Anna-Elina Lehtinen; Fariba Baghaei; Jan Astermark; Pål André Holme
Journal:  Haemophilia       Date:  2022-05-16       Impact factor: 4.263
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.